An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl

An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl

A single dose, randomized, complete and four treatment cross over study was conducted in healthy human subjects for IVIVC of venlafaxine.HCl, Plasma concentrations were estimated by a simple, rapid, sensitive and validated LCMS method, Cetirizine was used as the internal standard (IS), The analytes...

Full description

Bibliographic Details
Main Authors:	Aravindaraj, J.R., Manikandan, D., Nanjan, Moola Joghee
Format:	Article
Language:	English
Published:	São Paulo State University (UNESP) 2014-09-01
Series:	Revista de Ciências Farmacêuticas Básica e Aplicada
Subjects:	IVIVC Bioequivalence Dissolution Human plasma Venlafaxine HCl
Online Access:	http://serv-bib.fcfar.unesp.br/seer/index.php/Cien_Farm/article/view/3246/3246

Similar Items

An in vitro-in vivo correlation study of modified release formulations of Venlafaxine.HCl
by: J.R. Aravindaraj, et al.
Published: (2014-10-01)

Candesartan Cilexetil In Vitro–In Vivo Correlation: Predictive Dissolution as a Development Tool
by: Andrés Figueroa-Campos, et al.
Published: (2020-07-01)

Optimization and evaluation of venlafaxine hydrochloride fast dissolving oral films
by: Arwa Ibrahim Al-Mogherah, et al.
Published: (2020-11-01)

Application of mathematical modelling to alginate chitosan polyelectrolyte complexes for the prediction of system behavior with Venlafaxine HCl as a model charged drug
by: Howida K. Ibrahim, et al.
Published: (2022-10-01)

In Vivo Relevance of a Biphasic In Vitro Dissolution Test for the Immediate Release Tablet Formulations of Lamotrigine
by: Tuba Incecayir, et al.
Published: (2023-10-01)

Comparative Analysis between Controlled Release Paroxetine and Extended-Release Venlafaxine for Treatment of Depression
by: Vijay Kaul, et al.
Published: (2022-06-01)

Development and validation of stability indicating method for the quantitative determination of venlafaxine hydrochloride in extended release formulation using high performance liquid chromatography
by: Jaspreet Kaur, et al.
Published: (2010-01-01)

Venlafaxine Intoxication and Serotonin Syndrome
by: Mehmet Fatih Yörük, et al.
Published: (2018-10-01)

Venlafaxine-induced prostatism: a case report
by: Ibrahim Gundogmus, et al.
Published: (2017-04-01)

Is There a Potential of Misuse for Venlafaxine and Bupropion?
by: Fabrizio Schifano, et al.
Published: (2018-03-01)

Joint population pharmacokinetic modeling of venlafaxine and O-desmethyl venlafaxine in healthy volunteers and patients to evaluate the impact of morbidity and concomitant medication
by: Zhanzhang Wang, et al.
Published: (2022-12-01)

The Effect of Venlafaxine and Topiramate in Reducing Migraine Headaches in Patients with Abnormal Electroencephalogram
by: Fariborz Khorvash, et al.
Published: (2015-05-01)

Optimization of Nasal Liposome Formulation of Venlafaxine Hydrochloride using a Box-Behnken Experimental Design
by: Sulekha Khute, MPharm, et al.
Published: (2023-01-01)

In vivo dissolution of poorly water-soluble drugs: Proof of concept based on fluorescence bioimaging
by: Yinqian Yang, et al.
Published: (2021-04-01)

In Vitro–In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of Its Metabolite
by: Constantin Mircioiu, et al.
Published: (2019-07-01)

Persistant genital arousal disorder and venlafaxine: A case report
by: M. Marguilho, et al.
Published: (2021-04-01)

Multi-Compartmental Dissolution Method, an Efficient Tool for the Development of Enhanced Bioavailability Formulations Containing Poorly Soluble Acidic Drugs
by: Miklós Tamás Katona, et al.
Published: (2023-02-01)

Facial Flushing Associated with Anxiety and Improved by Venlafaxine: A Case Report
by: Qiu Y, et al.
Published: (2022-09-01)

Biorelevant drug release of Metformin dosage forms using complementary in vitro tools
by: Karl Box, et al.
Published: (2017-12-01)

The anti-inflammatory effects of venlafaxine in the rat model of carrageenan-induced paw edema
by: Valiollah Hajhashemi, et al.
Published: (2015-07-01)

Venlafaxine‐induced interstitial lung disease with COVID‐19 pandemic‐related depression
by: Akihito Okazaki, et al.
Published: (2022-06-01)

Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy
by: V.A. da-Silva, et al.
Published: (1999-01-01)

Rapid, Precise and Affordable Estimation of Venlafaxine and Its Metabolites in Highly Polluted Effluent Waters: Proof-of-Concept for Methodology
by: Snawar Hussain, et al.
Published: (2020-10-01)

A Case of Ruminative Hypomania Induced by High Dose Venlafaxine
by: E. Yıldızhan, et al.
Published: (2022-06-01)

Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats
by: J.G. Santos Junior, et al.
Published: (2002-04-01)

A rare case with suicide due to akathisia after use of single dose venlafaxine
by: Nermin Gündüz, et al.
Published: (2018-06-01)

Neuroleptic Malignant Syndrome After the Use of Venlafaxine in a Patient with Generalized Anxiety Disorder
by: Tsung-Chien Lu, et al.
Published: (2006-01-01)

Lithium and venlafaxine poisoning — a case report
by: Sinkovič Andreja, et al.
Published: (2013-10-01)

Comparison of efficacy and tolerability of escitalopram and venlafaxine in treatment-naïve patients with unipolar nonpsychotic depression: Is there a need to revisit the prescription patterns?
by: Harneet Kaur, et al.
Published: (2019-01-01)

Development and evaluation of gastroretentive floating tablets of an antidepressant drug by thermoplastic granulation technique
by: Harshal Ashok Pawar, et al.
Published: (2014-06-01)

Development of a New Type of Prolonged Release Hydrocodone Formulation Based on Egalet® ADPREM Technology Using In Vivo–In Vitro Correlation
by: Jean-Michel Cardot, et al.
Published: (2011-03-01)

Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures
by: R. Ryan Williams, et al.
Published: (2017-10-01)

In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations: Additional Evidence Regarding a Biopredictive Dissolution Medium
by: Marival Bermejo, et al.
Published: (2020-06-01)

Time course of effects of venlafaxine on migraine and generalized pruritus in a patient with depression
by: Yu Miyahara, et al.
Published: (2021-11-01)

DISSOLUTION TEST FOR MIANSERIN HYDROCHLORIDE IN TABLETS
by: Letícia Lenz Sfair, et al.
Published: (2019-12-01)

Editorial: Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites
by: Constantin Mircioiu, et al.
Published: (2021-05-01)

Venlafaxine-induced Thyroiditis: A Case Report
by: Ideh Ghafour, et al.
Published: (2018-09-01)

Venlafaxine-induced spontaneous ejaculation: Case report and literature review
by: I. Gundogmus, et al.
Published: (2022-06-01)

Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models
by: Vinod Burade, et al.
Published: (2017-06-01)

Development and validation of an HPLC-UV method for accelerated stability study and pharmacokinetic analysis of venlafaxine
by: Muhammad Sher, et al.
Published: (2020-03-01)